| 摘要: |
| 目的：探索新版医保目录的调整方向，为指导各省制定省级增补目录提供依据。方法：运用EXCEL和SPSS18.0对2009版《药品目录》和2017版《药品目录》进行对比分析，比较二者差异。结果：新版目录中药品种数增加明显，医保新增谈判药品目录；新版目录西药的分类方式发生改变；目录增补品种多，剔除药品少；医保目录新增剂型多为颗粒剂、口服液体制剂；甲乙类药品增长比例基本一致；国家增强了药品适应症支付限制，减少了对医保门诊的报销限定。结论：本次医保目录调整重点扶持中药和民族药，关注高值药品和儿童药，药品分类更为细化，目录管理日趋严格。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| The Contrast about National Reimbursement Drug List between 2009 and 2017 |
|
| () |
| Abstract: |
| Objective: To explore the adjustment direction of new National Reimbursement Drug List(NDRL) and provide guidance about supplement of Reimbursement Drug List for each province. Method: Comparing the difference about NDRL between 2009 and 2017 with instruments including EXCEL and SPSS18.0 . Results: More drugs and negotiated drugs are added into the new NDRL; The classification method of western drugs has been changed; The amount of supplementary drugs is more than eliminated drugs; The main dosage of supplementary drugs form is granules and Oral Liquid; The growth proportion of Class-A and Class-B is similar; The government has imposed restrictions on drug indication and canceled limit to r eimbursement of outpatient service. Conclusion: The new NDRL supports with the hand the T raditional Chinese medicine and pays more attention to expensive drugs and p ediatric drugs. It also subdivides the drug classification and make catalog management more strictly. |
| Key words: |
